Alnylam Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2015 | — | $1.26B | $180.9M |
| FY2016 | — | $920.2M | $193.6M |
| FY2017 | — | $1.77B | $645.4M |
| FY2018 | — | $1.30B | $420.1M |
| FY2019 | — | $1.44B | $547.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2015 | — | $1.26B | $180.9M |
| FY2016 | — | $920.2M | $193.6M |
| FY2017 | — | $1.77B | $645.4M |
| FY2018 | — | $1.30B | $420.1M |
| FY2019 | — | $1.44B | $547.2M |